Autopsy report · NCT04860635

Safety of F14 Following Total Knee Replacement

“Study superseded by alternative Phase 3 trial”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 100 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Phase

Phase 2, Phase 3

Sponsor

Arthritis Innovation Corporation

Sponsor type

Industry

Conditions

Analgesia

Interventions

F14 (sustained release celecoxib)

Participants

100 (planned, not actual)

Sites

2

Countries

United States

Trials that died the same way

• Evaluation of Biosynthetic Constructs to Replace Donor Corneas
  “This study was withdrawn to be replaced with a multi-site Phase I trial.” (73% match in meaning)
• Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
  “Trial did not move to Phase II portion due to poor tolerance of treatment” (69% match in meaning)
• A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
  “Focus resources on a planned phase 2/3 study” (68% match in meaning)
• Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
  “This study was terminated early due to other competing trials, therefore did not go on to the Phase II portion of the study.” (68% match in meaning)
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
  “Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II portion.” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.